Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02411916 · ClinicalTrials.gov registry record · NA
Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery
A NA study, sponsored by New York City Health and Hospitals Corporation.
- Completed
- Registry status
- NA
- Development phase
- 143
- Enrollment target
NCT02411916: Completed NA study, sponsored by New York City Health and Hospitals Corporation.
NCT02411916 is a NA study that has completed, run by New York City Health and Hospitals Corporation. The registered enrollment target is 143 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02411916, a NA study, has completed, sponsored by New York City Health and Hospitals Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 143 participants
- Enrollment target
Study Summary
This document defines the Clinical Investigation Protocol for a study designed to determine whether blood loss after spontaneous vaginal delivery is altered by the addition of misoprostol administration to the standard use of intravenous oxytocin after delivery. The protocol is an open-label randomized prospective trial to be carried out at Queens Hospital Center. Blood loss will be measured indirectly by comparing the maternal hemoglobin and hematocrit levels on admission in labor to those obtained within 24 hours after delivery.
Interventions
- BIOLOGICAL misoprostol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 143 participants |
| Start Date | 2012-03-30 |
| Est. Completion | 2019-02-16 |
| Phase | NA |
What the finished NCT02411916 record still lists
NCT02411916 is an interventional study that assigns participants to a tested intervention. The registered 143 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which misoprostol is the first listed.
NCT02411916 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02411916 about?
NCT02411916 is a clinical study titled "Effect of Adjunctive Misoprostol Treatment on Blood Loss at Vaginal Delivery". This document defines the Clinical Investigation Protocol for a study designed to determine whether blood loss after spontaneous vaginal delivery is altered by the addition of misoprostol administration to the standard use of intravenous oxytocin after delivery. The protocol is an open-label randomi...
What is the current status of trial NCT02411916?
This trial is currently completed. It is a NA study. The enrollment target is 143 participants. The study started on 2012-03-30. Estimated completion is 2019-02-16.
What interventions are being tested in trial NCT02411916?
The interventions under investigation include: misoprostol (BIOLOGICAL).
Who is sponsoring clinical trial NCT02411916?
This trial is sponsored by New York City Health and Hospitals Corporation, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02411916's enrollment target sits among peer trials
143 711th of 2000 higher than 1,290 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI